8-K: Achieve Life Sciences Q3 2025: Cytisinicline NDA Advances

Achieve Life Sciences announced its third quarter 2025 financial results and provided updates on its cytisinicline program, including an FDA PDUFA date and a National Priority Voucher for vaping cessation.

Summary

• Achieve Life Sciences reported a net loss of $14.4 million for the third quarter ended September 30, 2025, and $40.0 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $48.1 million as of September 30, 2025.
• The U.S. FDA accepted the cytisinicline New Drug Application (NDA) for treatment of nicotine dependence for smoking cessation in adults, assigning a PDUFA targeted action date of June 20, 2026.
• Achieve was awarded the FDA Commissioners National Priority Voucher (CNPV) for cytisinicline for treatment of nicotine dependence for e-cigarette or vaping cessation.
• New post hoc data published in Thorax demonstrated that cytisinicline significantly improved smoking quit rates compared to placebo in adults with chronic obstructive pulmonary disease (COPD).
• Key milestones were met in advancing the cytisinicline NDA, including submitting the 120-day safety update, concluding the ORCA-OL long-term exposure trial, and completing the final Data Safety Monitoring Committee (DSMC) review.
• Erik Atkisson was appointed as Chief Legal Officer in October 2025.

Sentiment

Score: 7

Explanation: While financial losses increased year-over-year, the company achieved significant regulatory and clinical milestones for cytisinicline, including FDA NDA acceptance, a PDUFA date, and a National Priority Voucher for vaping cessation. These advancements de-risk the primary asset and indicate strong operational momentum towards potential commercialization, outweighing the increased, but expected, pre-commercial expenses.

Positives

• FDA accepted the cytisinicline NDA for smoking cessation, reflecting the strength of the clinical development program.
• A PDUFA targeted action date of June 20, 2026, has been assigned for cytisinicline for smoking cessation.
• Awarded the FDA Commissioners National Priority Voucher for vaping cessation, which is expected to shorten review time to 1-2 months once materials are submitted.
• New post hoc data published in Thorax showed cytisinicline improved smoking quit rates in adults with COPD, supporting its potential in diverse populations.
• The ORCA-OL long-term safety trial concluded with all 334 participants completing one year of treatment, exceeding FDA's requested thresholds for patient exposure.
• The final DSMC review for the ORCA-OL trial found no concerns with respect to drug safety, with adverse events mostly mild in severity.
• The appointment of Erik Atkisson as Chief Legal Officer strengthens the leadership team for regulatory review and potential commercialization.

Negatives

• Total operating expenses for the three months ended September 30, 2025, increased to $14.7 million from $12.5 million in the prior year period.
• Total operating expenses for the nine months ended September 30, 2025, increased to $40.1 million from $26.9 million in the prior year period.
• Net loss for the three months ended September 30, 2025, increased to $14.4 million from $12.5 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $40.0 million from $27.5 million in the prior year period.
• Basic and diluted net loss per share for the nine months ended September 30, 2025, increased to $(0.99) from $(0.88) in the prior year period.

Risks

• Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially.
• Achieve may not achieve its plans or product development goals in a timely manner, if at all.
• Achieve may not successfully carry out its intentions or meet its expectations or projections disclosed in forward-looking statements.

Future Outlook

The company is preparing for potential commercialization of cytisinicline for smoking cessation following the PDUFA date of June 20, 2026. It is also advancing cytisinicline as a potential first-in-class treatment for vaping cessation, leveraging the Commissioners National Priority Voucher for potentially expedited review, addressing a significant and growing unmet medical need.

Management Comments

• Rick Stewart, CEO: "The FDA's acceptance of our NDA for cytisinicline in smoking cessation is an important milestone for Achieve, reflecting the strength of our clinical development program."
• Rick Stewart, CEO: "The vaping cessation market represents a significant and growing unmet medical need, with approximately 60% of the 17 million adult e-cigarette users in the United States expressing a desire to quit."
• Rick Stewart, CEO: "The momentum behind cytisinicline, from regulatory milestones to our preparations for commercial readiness, underscores our commitment to delivering hope and better health outcomes for millions of people."
• Dr. Mark Rubinstein, Interim CMO: "We have delivered important advancements in our cytisinicline development program, including receiving our PDUFA targeted action date for our smoking cessation indication and the Commissioners National Priority Voucher for vaping cessation."
• Dr. Mark Rubinstein, Interim CMO: "Additionally, new post hoc data published in Thorax showed consistent efficacy and safety results in adults with COPD, supporting further evaluation of the potential impact of cytisinicline in diverse populations."

Industry Context

The announcement highlights a significant unmet medical need in nicotine dependence, particularly for vaping cessation, where no FDA-approved treatments currently exist. Cytisinicline aims to be a new therapy in the smoking cessation indication, which has not seen a new treatment in nearly 20 years, and potentially the first for vaping cessation. The U.S. market for adult e-cigarette users is approximately 17 million, with 60% expressing a desire to quit, indicating a substantial market opportunity.

Comparison to Industry Standards

• Cytisinicline is positioned as a potential first-in-class treatment for vaping cessation, addressing a critical public health need with no current FDA-approved therapies.
• The smoking cessation market has not seen a new therapy in nearly 20 years, indicating cytisinicline could fill a significant gap in treatment options.
• The FDA Commissioners National Priority Voucher for e-cigarette or vaping cessation was awarded to only nine therapies, highlighting cytisinicline's recognized potential and importance within the industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant value creation if cytisinicline receives FDA approval and achieves successful commercialization, balanced against continued losses and cash burn in the near term.
• Patients (smokers/vapers): Hope for a new, effective treatment for nicotine dependence, addressing a major public health issue with high unmet need.
• Employees: Strengthened leadership team with the addition of a Chief Legal Officer, indicating growth and preparation for the commercial phase.
• Regulatory Authorities: Continued engagement with the FDA for NDA review and the vaping cessation program, with enhanced engagement expected due to the National Priority Voucher.

Next Steps

• Continued regulatory review of cytisinicline NDA for smoking cessation towards the June 20, 2026 PDUFA date.
• Advancing cytisinicline for vaping cessation, leveraging the Commissioners National Priority Voucher for potentially expedited review.
• Preparations for potential commercialization of cytisinicline for smoking cessation.

Key Dates

Recommendation

The company has achieved significant regulatory and clinical milestones for cytisinicline, including FDA NDA acceptance for smoking cessation with a PDUFA date set for June 20, 2026, and a National Priority Voucher for vaping cessation. These are strong indicators of the drug's potential and de-risk the development pathway. However, the company remains in a pre-revenue stage, reporting increased net losses and operating expenses for Q3 2025 and the nine months ended September 30, 2025. While the cash position of $48.1 million provides some runway, the high burn rate suggests future capital needs. The stock carries substantial risk until FDA approval and successful commercial launch, making a 'hold' recommendation appropriate for investors already positioned, awaiting further clarity on commercial prospects and financial sustainability.

Keywords

Achieve Life Sciences, ACHV, cytisinicline, nicotine dependence, smoking cessation, vaping cessation, FDA, NDA, PDUFA, biopharmaceutical, Q3 2025 earnings, pharmaceutical, clinical trials, ORCA-2, ORCA-3, ORCA-OL, COPD